Cardiac rehabilitation with a nurse case manager (GoHeart) across local and regional health authorities improves risk factors, self-care and psychosocial outcomes. A one-year follow-up study

Journal of the Royal Society of Medicine Cardiovascular Disease 0(0) 1-11 © The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10 1177/2048004014555922 cvd.sagepub.com



# Vibeke Brogaard Hansen<sup>1</sup> and Helle Terkildsen Maindal<sup>2</sup>

# Abstract

**Objectives:** In Denmark, the local and regional health authorities share responsibility for cardiac rehabilitation (CR). The objective was to assess effectiveness of CR across sectors coordinated by a nurse case manager (NCM). Design: A one-year follow-up study.

Setting: A CR programme (GoHeart) was evaluated in a cohort at Lillebaelt Hospital Vejle, DK from 2010 to 2011. Participants: Consecutive patients admitted to CR were included. The inclusion criteria were the event of acute myocardial infarction or stable angina and invasive revascularization (left ventricular ejection fraction (LVEF)  $\geq$ 45%).

Main outcome measures: Cardiac risk factors, stratified self-care and self-reported psychosocial factors (SF12 and Hospital Anxiety and Depression Scale (HADS)) were assessed at admission (phase IIa), at three months at discharge (phase IIb) and at one-year follow-up (phase III). Intention-to-treat and predefined subgroup analysis on sex was performed.

Results: Of 241 patients, 183 (75.9%) were included (mean age 63.8 years). At discharge improvements were found in total-cholesterol (p < 0.001), low density lipoprotein (LDL; p < 0.001), functional capacities (metabolic equivalent of tasks (METS), p < 0.01), self-care management (p < 0.001), Health status Short Form 12 version (SF12; physical; p < 0.001 and mental; p < 0.01) and in depression symptoms (p < 0.01). At one-year follow-up these outcomes were maintained; additionally there was improvement in body mass index (BMI; p < 0.05), and high density lipoprotein (HDL; p < 0.05). There were no sex differences.

Conclusion: CR shared between local and regional health authorities led by a NCM (GoHeart) improves risk factors, self-care and psychosocial factors. Further improvements in most variables were at one-year follow-up.

#### **Keywords**

Cardiac rehabilitation, public health policy, shared care, nurse case manager, health status, self-care management, depression, prevention

# Introduction

Since 2007, the local and regional health authorities in Denmark have shared responsibility for prevention, health promotion and physical rehabilitation for patients with chronic cardiovascular disease after hospitalisation. The outcome of cardiac rehabilitation (CR) in the transition between hospital and municipal is not well-documented. Studies suggest that several patients opt out from the recommended sequence due to lack of information and interruptions, when the health care delivery task is cooperated across sectors. This encourages the need for Shared Care between sectors.<sup>1,2</sup> The use of proactive support across sectors, e.g. through a nurse case manager (NCM), has proved effective in chronic disease management.<sup>3,4</sup>

<sup>1</sup>Department of Cardiology, Lillebaelt Hospital Vejle, Denmark <sup>2</sup>Section of Health Promotion and Health Services, Department of Public Health, Aarhus University, Denmark

#### **Corresponding author:**

Vibeke Brogaard Hansen, Department of Cardiology, Kabbeltoft 25, Lillebaelt Hospital Vejle, DK-7100 Vejle, Denmark. Email: v. brogaard@dadlnet.dk

(cc)

Creative Commons CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www. creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(http://www.uk.sagepub.com/aboutus/openaccess.htm).

Another challenge for CR is sex differences in health outcomes. It is well-known from primary prevention that women do not perceive heart disease as a priority health concern, or they have less obvious symptoms.<sup>5</sup> Further, women have lower compliance rates and completeness of programme.<sup>6</sup> Therefore, the development of methods to enhance women's compliance in healthcare settings should be included when developing programme.


We have previously shown that the implementation of a NCM compared to usual care reduces the number of patients who refuse to participate in CR from 25% to 5% and increase the number of patients who participate in the CR at the municipality from 46% to 58% with no sex differences.<sup>7</sup>

The aim of this study was to assess effectiveness of CR across local and regional health authorities coordinated by a NCM at clinical, self-care and psychosocial outcomes at discharge from hospital after three months (phase IIb) and one-year follow-up (phase III).

# Methods

### Design, setting and study population

Figure 1 shows the Danish single-centre CR programme GoHeart. The programme was conducted between the Department of Cardiology, Lillebaelt Hospital Vejle and the Municipal Health Centre Vejle. The programme was in accordance with the European Society of Cardiology (ESC) guidelines.<sup>8</sup> The Shared Care between hospital and the municipality was standardised as were the components of the hospital-based NCM responsibility across the hospital and municipality sectors.9 Key components of the NCM were administration, direct patient support and enhanced support for vulnerable patients with low self-management (Table 1). In agreement with the local general practitioners (GPs) and approval from the patient the NCM made telephone contact to the GP at discharge if the patient was stratified with high risk including low self-care management to ensure a follow-up in phase III (Figure 1). The NCM provided



4) Telephone contact to the General Practitioner (GP) by the Nurse Care Manager if a high risk individual (Chronic Care Model)

Figure 1. Flow chart of the cardiac multidisciplinary rehabilitation programme for cohort (GoHeart).

risk stratified care management using the Chronic Care Model risk stratification tool<sup>10,11</sup> based on psychosocial risk factors, disease complexity and self-care management. As all patients included had chronic ischaemic heart disease (IHD) they were stratified to differentiated CR programme according to their self-care level (low or high).

# Patient enrolment and inclusion criteria

Consecutive patients admitted to CR in the period from September 2010 to November 2011 at the Department of Cardiology, Lillebaelt Hospital Vejle were asked to participate in the study at the nurse CR admission consultation (Figure 1 and Figure 2). The criteria for CR were the event of acute myocardial infarction (MI) or stabile angina and coronary angiography at the Department leading to assessment of revascularisation at the associated centres (percutaneous transluminal coronary intervention (PCI), coronary artery bypass grafting (CABG) with or without combination of valve replacement or recommendation of a conservative strategy). Exclusion criteria were heart failure (left ventricular ejection fraction (LVEF) <45%). These patients received CR through the heart failure clinic.

In total 315 patients fulfilled the criteria for CR in the period (Figure 2). Twenty-three (7.3%) patients refused participation mainly due to previous CR. Further reasons were alcohol abuse and severe psychiatric disease, found it unnecessary or because of workload. Overall 292 patients accepted admission to CR and were invited to participate in the study. The NCM contacted non-responders (to the questionnaires) or drop-outs (absent at the clinical follow-up measurements) by telephone after two weeks. If there was no response to this telephone call a postal reminder was sent. Participants were excluded from the analysis upon failure to respond to the follow-up (Figure 2).

#### Data collection and measurements

The outcome variables were obtained from clinical records and self-reported questionnaires (Tables 2 and 3) at admission in phase IIa (baseline), after three months at discharge in phase IIb, and at one-year follow-up in phase III.<sup>1</sup> The following socio-demographic data were collected: sex, age, marital status, education level, nationality, housing and labour market status.

Clinical measures and risk behaviour. Height and weight were measured, and body mass index (BMI) was calculated. Blood pressure was monitored in the supine position. A blood sample was drawn non-fasting to measure lipids (total-cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL) and triglycerides) and HbA1c in people with diabetes (n = 32). Alcohol consumption was measured in unit

Administration	Direct patient support	Enhanced support for vulnerable patients
<ul> <li>Management of the patient distribution to cardiac rehabilitation<sup>a</sup></li> <li>Booking and alter the course as individually required with focus on minimizing opt-outs</li> <li>Focus on vacant training and educational course ensuring max capacity and short waiting time</li> <li>Facilitate and inform the patients<sup>a</sup></li> <li>Arrange transport and interpreter as needed<sup>a</sup></li> <li>Follow-up when patient fails to appear</li> <li>Electronic and verbal communication between collaborative professionals<sup>a</sup></li> <li>Arrange meetings for the rehabilitation team both interdisciplinary and cross-sectorial</li> <li>Contact by the Department to the Municipal Authorities and the General Practitioners</li> </ul>	Inform the patients about the cardiac rehabilitation treatment measures and opportunities <sup>a</sup> Individual adjustment Based on stratification, clarify needs, resources and motivation Provide guidance to patients by telephone through a 'hotline' and writing by mailbox Ensure individual nurse contact 'Life line'	Optimise the course individually with the aim of receiving an entire or, as minimum, part of the recommended cardiac rehabilitation Opportunity of individual counseling Telephone message to the general practitioner when discharged from hospital

Table 1. Key components of the nurse case management at the Department of Cardiology, Lillebaelt Hospital, Vejle, Denmark.

<sup>a</sup>Usual cardiac rehabilitation.




Figure 2. Flow chart for the GoHeart-study.

per week. Smoking was divided into current, previous and never smoking (Tables 2 and 3).

Exercise capacity was measured by a treadmill exercise test<sup>12</sup> combined with the Borg15 talk test<sup>13</sup> at the Hospital (Figure 1). At follow-up at the Municipal Health Centre, the patients were tested by the Borg15 talk test only, since the treadmill exercise test was not an option. Patients, who were unable to perform the initial test, had a 6-min walk test initial. This was only an option at the hospital (n=7) (Table 2).

*Psychosocial measures.* Participants' self-care management was determined by the NCM using the criteria from Chronic Care Model.<sup>10,11</sup> This was determined according to how the patient engaged to promote

health, to augment physical, social or emotional resources and to prevent sequela.

The self-reported health status was measured using the Short-Form 12 version 2 (SF-12v2) with psychical (pcs) and mental (mcs) component summery scores.<sup>14</sup> Anxiety and depression were measured by the Hospital Anxiety and Depression Scale (HADS).<sup>15,16</sup> Participants scoring HADS anxiety  $\geq 8$  or depression  $\geq 8$  were encouraged to contact their GP.

Psychosocial measures were not taken at baseline due to the acute condition the patients were in.

Data at each of the follow-up times were transferred to the research database and checked for errors. If errors were encountered, the original questionnaire was investigated and the database entry corrected.

FemaleMale $p$ value $Ail$ 44 (24.0)139 (76.0)139 (76.0)19 (32.8)44 (24.0)139 (76.0)139 (76.0)19 (32.8)66.5 (9.7)62.9 (8.6)0.02061.6 (13.0)5 (11.4)27 (19.4)0.28615 (25.9)5 (11.4)27 (19.4)0.2625 (8.6)29 (65.9)92 (66.2)1,00042 (72.4)2 (4.6)1 (0.7)0.11441 (17)0 (0.0)0 (0.0)0.00117 (12.1)2 (4.6)1 (0.7)0.14441 (17)2 (4.6)1 (0.7)0.14441 (17)2 (4.6)1 (0.7)0.14441 (17)2 (4.6)1 (0.7)0.14441 (17)2 (4.6)1 (0.7)0.14441 (17)2 (4.6)1 (0.7)0.14441 (17)2 (4.6)0 (0.0)0.14441 (17)2 (4.6)0 (0.0)0.14441 (17)2 (4.6)0 (0.0)0.14441 (17)2 (4.6)0 (0.0)0.57715 (25.9)2 (4.1)6 (49.6)0.86327 (46.6)8 (18.2)15 (10.8)0.5569 (16.1)15 (34.1)84 (60.4)0.2569 (16.1)15 (34.1)6 (43)0.2569 (16.1)3 (682)9 (71.2)0.70836 (62.1)3 (682)9 (71.2)0.70836 (62.1)3 (682)9 (71.2)0.70836 (62.1)3 (773)1 (1 (82.0)0.51258 (100)3 (773)1 (4 (82.0) <t< th=""><th></th><th>Participants</th><th></th><th></th><th></th><th>Non-responders</th><th>ers</th><th>Non-participants</th><th>nts</th></t<>		Participants				Non-responders	ers	Non-participants	nts
met $44 (240)$ $139 (760)$ $39 (672)$ $0.181$ $r$ disease $4 (240)$ $139 (760)$ $39 (672)$ $0.181$ r disease $313 (90)$ $655 (97)$ $629 (8.6)$ $0.020$ $61.6 (13.0)$ $0.161$ r disease $312 (75)$ $5 (11.4)$ $27 (19.4)$ $0.226$ $5 (8.5)$ $0.142$ EM $32 (175)$ $5 (11.4)$ $27 (19.4)$ $0.222$ $5 (8.6)$ $0.142$ EM $32 (175)$ $5 (11.4)$ $27 (19.4)$ $0.222$ $5 (8.6)$ $0.142$ ment $31 (1.6)$ $2 (75)$ $2 (4.6)$ $1 (0.7)$ $0.11$ $7 (12.1)$ $0.43$ Met $3 (1.6)$ $0 (0.0)$ $0 (0.0)$ $0 (0.0)$ $0 (0.0)$ $0 (1.7)$ $0.142$ Met $3 (1.6)$ $2 (7.4)$ $2 (7.4)$ $0 (2.5)$ $0 -467$ Met $3 (1.2)$ $2 (7.4)$ $0 (2.5)$ $0 (2.5)$ $0 -467$ Met $3 (1.2)$ $2 (1.5)$ $0 (2.5)$	Characteristics	All N = 183	Female	Male	anley d	AII N = 58	b value	All N = 51	h value
math $44 (240)$ $137 (760)$ $19 (32.9)$ $0.188$ math $(yerrs), mean (SD)$ $63.8 (9.7)$ $65.5 (9.7)$ $62.9 (8.6)$ $0.020$ $61.6 (13.0)$ $0.161$ rt disease $38 (20.8)$ $12 (27.3)$ $56.1 (9.7)$ $62.9 (8.6)$ $0.020$ $61.6 (13.0)$ $0.161$ STEMI $38 (20.8)$ $12 (27.3)$ $5 (11.4)$ $27 (19.4)$ $0.226$ $5 (8.6)$ $0.142$ EVI $32 (17.5)$ $5 (11.4)$ $27 (19.4)$ $0.226$ $5 (8.6)$ $0.142$ ment $12 (17.5)$ $5 (11.4)$ $27 (19.4)$ $0.226$ $5 (8.6)$ $0.142$ ment $12 (17.5)$ $5 (11.4)$ $27 (19.4)$ $0.236$ $5 (8.6)$ $0.142$ ment $12 (17.5)$ $2 (14.6)$ $0.226$ $9 (15.7)$ $0.47$ $0.47$ $13 (100)$ $12 (17.7)$ $2 (14.6)$ $0.232$ $2 (14.6)$ $0.467$ $14 (120)$ $12 (17.7)$ $2 (14.6)$ $0.232$ $2 (14.6)$ $0.467$ <th></th> <th></th> <th></th> <th>- 1410</th> <th>P raise</th> <th></th> <th>P value</th> <th></th> <th></th>				- 1410	P raise		P value		
44 (24.0) $44 (24.0)$ $139 (75.0)$ $139 (75.0)$ $139 (72.2)$ $0.188$ 139 (75.0) $65.5 (9.7)$ $6.29 (8.5)$ $0.020$ $61.6 (13.0)$ $0.161$ 38 (70.0) $65.5 (9.7)$ $6.29 (8.5)$ $0.020$ $61.6 (13.0)$ $0.161$ 32 (17.5) $5 (11.4)$ $27 (19.4)$ $0.226$ $5 (8.6)$ $0.142$ 32 (17.5) $5 (11.4)$ $27 (19.4)$ $0.222$ $5 (8.6)$ $0.142$ 32 (17.5) $2 (4.6)$ $10.07$ $0.011$ $7 (12.1)$ $0.457$ $32 (17.5)$ $2 (4.6)$ $10.077$ $0.144$ $1 (17)$ $0.045$ $31 (8.0)$ $10 (22.7)$ $28 (20.1)$ $0.677$ $0.72.9$ $0.467$ $33 (8.0)$ $10 (22.7)$ $28 (20.1)$ $0.677$ $15 (25.9)$ $0.467$ $32 (12.6)$ $8 (18.2)$ $10 (22.7)$ $28 (20.1)$ $0.677$ $15 (25.9)$ $0.467$ $31 (8.0)$ $10 (22.7)$ $28 (20.1)$ $0.677$ $10 (20.9)$ $0.633$ $32 (12.6)$ $8 (18.2)$ $10 (20.9)$ $0.256$ $9 (1$	Sex								
138 (76.0) $137 (76.0)$ $39 (67.2)$ 638 (9.0) $66.5 (77)$ $62.9 (8.6)$ $0.020$ $61.6 (13.0)$ $0.161$ 38 (208)       12 (27.3) $26 (18.7)$ $0.286$ $15 (25.9)$ $0.467$ 32 (17.5) $5 (11.4)$ $27 (19.4)$ $0.262$ $5 (8.6)$ $0.142$ 121 (66.1) $29 (65.9)$ $92 (66.2)$ $1.000$ $42 (72.4)$ $0.467$ 32 (17.5) $2 (4.6)$ $10.7 (12.1)$ $0.412$ $0.412$ 32 (17.5) $2 (4.6)$ $10.7 (10.7)$ $0.142$ $0.457$ 32 (17.5) $2 (4.6)$ $10.7 (12.1)$ $0.423$ $0.457$ 33 (18.0) $12 (27.3)$ $21 (5.1)$ $0.77 (2.1)$ $0.423$ 38 (20.8) $10 (22.77)$ $28 (20.1)$ $0.577 (4.6.6)$ $0.563$ 38 (20.8) $10 (22.77)$ $28 (20.1)$ $0.577 (4.6.6)$ $0.563$ 38 (20.8) $10 (22.77)$ $28 (20.1)$ $0.577 (4.6.6)$ $0.563$ 38 (20.8) $10 (22.77)$ $28 (20.1)$ $0.577 (4.6.6)$ $0.563$ 38 (20.8) $10 (22.77)$ <td>Female</td> <td></td> <td>44 (24.0)</td> <td></td> <td></td> <td>19 (32.8)</td> <td>0.188</td> <td>15 (29.4)</td> <td>0.435</td>	Female		44 (24.0)			19 (32.8)	0.188	15 (29.4)	0.435
63.8 (9.0)         66.5 ( $9.7$ )         6.29 (8.6)         0.020         61.6 (13.0)         0.161           38 (20.8)         12 (27.3)         26 (18.7)         0.286         15 (25.9)         0.447           32 (17.5)         5 (11.4)         27 (19.4)         0.262         5 (8.6)         0.142           31 (15.5)         5 (1.4)         27 (19.4)         0.262         5 (8.6)         0.142           32 (17.5)         5 (1.4)         27 (19.4)         0.262         5 (8.6)         0.142           31 (16.1)         29 (65.9)         92 (66.2)         1.000         42 (72.4)         0.473           32 (17.5)         2 (4.6)         30 (21.6)         0011         7 (12.1)         0.415           31 (16.0)         2 (4.6)         10.77         0.144         1 (17)         1.000           arisation         0 (0.0)         0 (0.0)         0 (0.0)         0 (0.0)         0.467           32 (17.5)         2 (4.6)         1 (0.77)         2 (2.01)         0.677         15 (25.9)         0.447           33 (18.0)         12 (27.3)         21 (51.1)         0.75         9 (15.5)         0.467           33 (26.9)         10 (22.77)         28 (20.1)         0.677         15 (25.9)	Male			139 (76.0)		39 (67.2)		36 (70.6)	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Age (years), mean (SD)	63.8 (9.0)	66.5 (9.7)	62.9 (8.6)	0.020	61.6 (13.0)	0.161	68.0 (11.6)	0.006
38 (208) $12$ (27.3) $26$ (18.7) $0.286$ $15$ (25.9) $0.467$ 32 (17.5) $5$ (11.4) $27$ (19.4) $0.262$ $5$ (8.6) $0.142$ 121 (66.1) $29$ (65.5) $92$ (66.2) $1,000$ $42$ (72.4) $0.453$ 32 (17.5) $2$ (4.6) $10.7$ ) $0.011$ $7$ (12.1) $0.415$ 33 (16.0) $0$ (0.0) $0$ (0.0) $0$ (0.0) $0.011$ $7$ (12.1) $0.415$ 33 (18.0) $12$ (27.3) $21$ (15.1) $0.075$ $9$ (15.5) $0.843$ 38 (20.8) $10$ (22.7) $28$ (20.1) $0.677$ $9$ (15.5) $0.843$ 38 (20.8) $10$ (22.7) $28$ (20.1) $0.677$ $9$ (15.5) $0.843$ 38 (20.8) $10$ (22.7) $28$ (20.1) $0.677$ $9$ (15.5) $0.467$ 38 (20.8) $10$ (22.7) $28$ (20.1) $0.677$ $9$ (15.5) $0.467$ 38 (20.8) $10$ (22.7) $28$ (20.1) $0.677$ $9$ (15.5) $0.467$ 38 (20.8) $10$ (22.7) $28$ (20.1) $0.577$ $9$ (16.1)	Heart disease								
38 (208) $12 (27.3)$ $26 (18.7)$ $0.286$ $15 (35.9)$ $0.467$ 32 (17.5) $5 (11.4)$ $27 (19.4)$ $0.262$ $5 (8.6)$ $0.142$ 121 (66.1) $29 (65.9)$ $92 (66.2)$ $1.000$ $42 (72.4)$ $0.433$ 32 (17.5) $2 (4.6)$ $1 (0.7)$ $0.114$ $1 (17)$ $1.000$ $3 (1.6)$ $2 (4.6)$ $1 (0.7)$ $0.144$ $1 (17)$ $1.000$ $3 (1.6)$ $2 (4.6)$ $1 (0.27)$ $0.144$ $1 (17)$ $1.000$ $3 (1.6)$ $0 (0.0)$ $0 (0.0)$ $0 (0.0)$ $0 (0.0)$ $0.467$ $3 (18.0)$ $12 (2773)$ $21 (15.1)$ $0.077$ $9 (15.5)$ $0.467$ $3 (20.8)$ $10 (22.7)$ $28 (20.1)$ $0.677$ $15 (25.9)$ $0.467$ $3 (12.6)$ $8 (18.2)$ $12 (71.2)$ $0.863$ $27 (46.6)$ $0.653$ $3 (12.6)$ $8 (18.2)$ $15 (10.8)$ $0.2569$ $9 (15.1)$ $0.673$ $3 (20.6)$ $10 (22.7)$ $28 (20.1)$ $0.677$ $14 (6.9)$ $0.653$ $0.663$	IΣ								
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	NSTEMI	38 (20.8)	12 (27.3)	26 (18.7)	0.286	15 (25.9)	0.467	10 (19.6)	000.1
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	STEMI	32 (17.5)	5 (11.4)	27 (19.4)	0.262	5 (8.6)	0.142	I (2.0)	0.003
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Treatment								
32 (17.5)         2 (4.6)         30 (21.6)         0.011         7 (12.1)         0.415           Iarisation         3 (1.6)         2 (4.6)         1 (0.7)         0.144         1 (17)         1.000           Iarisation         0 (0.0)         0 (0.0)         0 (0.0)         0 (0.0)         0 (0.0)         0 (0.0)           33 (18.0)         12 (27.3)         21 (15.1)         0.075         9 (15.5)         0.843           38 (20.8)         10 (22.7)         28 (20.1)         0.677         15 (25.9)         0.467           38 (20.8)         10 (22.7)         28 (20.1)         0.677         15 (25.9)         0.467           92 (50.3)         23 (52.3)         69 (49.6)         0.863         27 (46.6)         0.653           92 (50.3)         23 (52.4)         21 (477)         84 (60.4)         0.250         14 (25.0)           55 (30.1)         15 (34.1)         40 (28.8)         9 (16.1)         9 (16.1)         0.303           55 (30.1)         15 (34.8)         0 (0.0)         7 (5.0)         0.199         4 (6.9)         0.303           55 (30.1)         15 (34.1)         40 (28.8)         0.256         9 (16.1)         0.255           7 (3.8)         0 (0.0)         7 (5.	PCI	121 (66.1)	29 (65.9)	92 (66.2)	1,000	42 (72.4)	0,423	36 (70.6)	0,615
Iderisation $3 (1.6)$ $2 (4.6)$ $1 (0.7)$ $0.144$ $1 (17)$ $1.000$ Iarisation $0 (0.0)$ $0 (0.0)$ $0 (0.0)$ $0 (0.0)$ $0 (0.0)$ $33 (18.0)$ $12 (27.3)$ $21 (15.1)$ $0.075$ $9 (15.5)$ $0.843$ $38 (20.8)$ $10 (22.7)$ $28 (20.1)$ $0.677$ $15 (25.9)$ $0.467$ $32 (12.6)$ $8 (18.2)$ $15 (10.8)$ $0.653$ $27 (46.6)$ $0.653$ $23 (12.6)$ $8 (18.2)$ $15 (10.8)$ $33 (58.9)$ $<0.0001$ $105 (57.4)$ $21 (477)$ $84 (60.4)$ $0.250$ $14 (25.0)$ $55 (30.1)$ $15 (10.8)$ $0.250$ $14 (25.0)$ $55 (30.1)$ $15 (10.8)$ $0.256$ $8 (13.8)$ $0.303$ $55 (30.1)$ $15 (10.8)$ $0.256$ $8 (13.8)$ $0.466$ $7 (3.8)$ $0 (0.0)$ $7 (5.0)$ $0.199$ $4 (6.9)$ $0.303$ $5 (30.1)$ $15 (10.8)$ $0.569$ $8 (13.8)$ $0.466$ $7 (3.8)$ $0 (0.0)$ $7 (5.0)$ $0.199$ $4 (6.9)$ $0.303$ $5 (30.1)$ $15 (10.8)$ $0.569$ $8 (13.8)$ $0.466$ $10 (5.5)$ $4 (9.1)$ $6 (4.3)$ $0.226$ $9 (16.1)$ $0.227$ $129 (70.5)$ $30 (68.2)$ $9 (71.2)$ $0.708$ $36 (62.1)$ $0.257$ $148 (80.9)$ $34 (77.3)$ $114 (82.0)$ $0.512$ $58 (100)$ $-0.0001$ $148 (80.9)$ $34 (77.3)$ $114 (82.0)$ $0.512$ $58 (100)$ $-0.001$	CABG	32 (17.5)	2 (4.6)	30 (21.6)	0.011	7 (12.1)	0.415	6 (11.8)	0.395
Invisation $0 (0.0)$ $0 (0.0)$ $0 (0.0)$ $0 (0.0)$ 33 (18.0)12 (27.3)21 (15.1) $0.075$ $9 (15.5)$ $0.843$ 38 (20.8)10 (22.7)28 (20.1) $0.677$ 15 (25.9) $0.467$ 38 (20.3)23 (52.3)69 (49.6) $0.863$ $27 (46.6)$ $0.653$ 23 (12.6)8 (18.2)15 (10.8)33 (58.9) $-0.0001$ 105 (57.4)21 (47.7)84 (60.4) $0.250$ 14 (25.0)55 (30.1)15 (34.1)40 (28.8) $9 (16.1)$ $9 (16.1)$ 55 (30.1)15 (34.1)40 (28.8) $0.199$ $4 (6.9)$ $0.303$ 57 (3.8) $0 (0.0)$ 7 (5.0) $0.199$ $4 (6.9)$ $0.303$ 58 (30.1)15 (10.8) $0.569$ $8 (13.8)$ $0.466$ 7 (3.8) $0 (0.0)$ 7 (5.0) $0.199$ $4 (6.9)$ $0.303$ 5 (30.1)15 (10.8) $0.569$ $8 (13.8)$ $0.202$ 7 (3.8) $0 (0.0)$ 7 (5.0) $0.199$ $4 (6.9)$ $0.303$ 5 (30.1)3 (68.2) $99 (71.2)$ $0.708$ $3 (62.1)$ $0.257$ 129 (70.5)30 (68.2) $99 (71.2)$ $0.708$ $3 (62.1)$ $0.257$ 129 (70.5) $34 (77.3)$ $114 (82.0)$ $0.512$ $58 (100)$ $-0.0001$ 148 (80.9) $34 (77.3)$ $114 (82.0)$ $0.512$ $58 (100)$ $-0.0001$	Aortic substitution $\pm$ revascularisation	3 (1.6)	2 (4.6)	1 (0.7)	0.144	1 (17)	1.000	3 (5.9)	0.119
33 (180)       12 (27.3)       21 (15.1) $0.075$ 9 (15.5) $0.843$ 38 (20.8)       10 (22.7)       28 (20.1) $0.677$ 15 (25.9) $0.467$ 92 (50.3)       23 (52.3)       69 (49.6) $0.863$ 27 (46.6) $0.653$ 92 (50.3)       23 (12.6)       8 (18.2)       15 (10.8) $33 (58.9)$ $0.6001$ 105 (57.4)       21 (47.7)       84 (60.4) $0.250$ 14 (25.0) $0.653$ 53 (10.1)       15 (34.1)       40 (28.8) $0.250$ 14 (25.0) $0.303$ 57 (30.1)       15 (30.1)       15 (10.8) $0.256$ 8 (13.8) $0.466$ 7 (3.8) $0 (0.0)$ 7 (5.0) $0.199$ 4 (6.9) $0.303$ 5 (30.1)       15 (10.8) $0.569$ 8 (13.8) $0.466$ 7 (3.8) $0 (0.0)$ 7 (5.0) $0.199$ $4 (6.9)$ $0.303$ 5 (30.1)       15 (34.1) $40 (28.8)$ $0.256$ $9 (16.1)$ $0.267$ 7 (3.8) $0 (0.0)$ 7 (5.0) $0.199$ $4 (6.9)$ $0.303$ 1 (16.7)       38 (68.4)       12 (10.8)       <	Mitral substitution $\pm$ revascularisation	0 (0.0)	0 (0.0)	0 (0:0)		0 (0.0)		I (2.0)	0.218
38 (20.8)         10 (22.7)         28 (20.1) $0.677$ 15 (25.9) $0.467$ 92 (50.3)         23 (52.3)         69 (49.6) $0.863$ 27 (46.6) $0.653$ 92 (50.3)         23 (12.6)         8 (18.2)         15 (10.8) $33 (58.9)$ $-0.0001$ 105 (57.4)         21 (47.7)         84 (60.4) $0.250$ 14 (25.0) $0.653$ 55 (30.1)         15 (34.1)         40 (28.8) $0.250$ 14 (25.0) $9 (16.1)$ 55 (30.1)         15 (34.1)         40 (28.8) $0.256$ $9 (16.1)$ $0.303$ 7 (3.8)         0 (0.0)         7 (5.0) $0.199$ $4 (6.9)$ $0.303$ 7 (3.8)         0 (0.0)         7 (5.0) $0.199$ $4 (6.9)$ $0.303$ 7 (3.8)         0 (0.0)         7 (5.0) $0.199$ $4 (6.9)$ $0.303$ 7 (3.8)         0 (0.0)         7 (5.0) $0.199$ $4 (6.9)$ $0.303$ 9 (16.1)         0 (5.5) $3 (6.82)$ $9 (71.2)$ $0.766$ $9 (15.5)$ $0.257$ 10 (5.5) $3 (68.4)$ $12 (92.$	Conservative strategy	33 (18.0)	12 (27.3)	21 (15.1)	0.075	9 (15.5)	0.843	7 (13.7)	0.535
92 (50.3)       23 (52.3)       69 (49.6) $0.863$ 27 (46.6) $0.653$ 23 (12.6)       8 (18.2)       15 (10.8)       33 (58.9)       <0.0001	Known IHD	38 (20.8)	10 (22.7)	28 (20.1)	0.677	15 (25.9)	0.467	19 (37.3)	0.026
92 (50.3)       23 (52.3)       69 (49.6)       0.863       27 (46.6)       0.653         23 (12.6)       8 (18.2)       15 (10.8)       33 (58.9)       <0.0001	Cardiovascular risk factors								
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Family history of IHD	92 (50.3)	23 (52.3)	69 (49.6)	0.863	27 (46.6)	0.653	23 (45.1)	0.531
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Smoking history								
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Current smokers	23 (12.6)	8 (18.2)	15 (10.8)		33 (58.9)	< 0.000 I	18 (36.0)	0.001
55 (30.1)       15 (34.1)       40 (28.8)       9 (16.1)         5 $7$ (3.8)       0 (0.0)       7 (5.0)       0.199       4 (6.9)       0.303         7       (3.8)       0 (0.0)       7 (5.0)       0.199       4 (6.9)       0.303         8       18 (9.8)       3 (6.8)       15 (10.8)       0.569       8 (13.8)       0.466         10 (5.5)       4 (9.1)       6 (4.3)       0.256       9 (15.5)       0.022         129 (70.5)       30 (68.2)       99 (71.2)       0.708       36 (62.1)       0.257         167 (91.3)       38 (86.4)       129 (92.8)       0.221       0.00       0.257         2 (1.1)       0 (0.0)       2 (1.4)       1,000       0 (0.0)       1.000         148 (80.9)       34 (77.3)       0.512       58 (100)       <0.0001	Previous smoker	105 (57.4)	21 (47.7)	84 (60.4)	0.250	14 (25.0)		18 (36.0)	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Never smokers	55 (30.1)	15 (34.1)	40 (28.8)		9 (16.1)		14 (28.0)	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Diabetes								
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Only diet treatment	7 (3.8)	0 (0.0)	7 (5.0)	0.199	4 (6.9)	0.303	2 (3.9)	000 <sup>.</sup> I
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Medically treated with tablets	18 (9.8)	3 (6.8)	15 (10.8)	0.569	8 (13.8)	0.466	3 (5.9)	0.580
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Medically treated with insulin	10 (5.5)	4 (9.1)	6 (4.3)	0.256	9 (15.5)	0.022	5 (9.8)	0.329
167 (91.3) 38 (86.4) 129 (92.8) 0.221 2 (1.1) 0 (0.0) 2 (1.4) 1,000 0 (0.0) 1.000 148 (80.9) 34 (77.3) 114 (82.0) 0.512 58 (100) <0.0001	Medically treated hypertension	129 (70.5)	30 (68.2)	99 (71.2)	0.708	36 (62.1)	0.257	40 (78.4)	0.294
2 (1.1) 0 (0.0) 2 (1.4) 1,000 0 (0.0) 1.000 148 (80.9) 34 (77.3) 114 (82.0) 0.512 58 (100) <0.0001	Hypercholesterolemia	167 (91.3)	38 (86.4)	129 (92.8)	0.221				
148 (80.9) 34 (77.3) 114 (82.0) 0.512 58 (100) <0.0001	Diet treated	2 (1.1)	0 (0.0)	2 (1.4)	1,000	0 (0.0)	1.000	3 (5.9)	0.071
	Medically treated	148 (80.9)	34 (77.3)	114 (82.0)	0.512	58 (100)	< 0.000 I	48 (94.1)	0:030

τ	J
٩	)
	5
Ē	
_÷Ξ	5
2	
Ē	)
Ū	)
· ·	
2	i
٩	)
3	2
	ì
Ĥ	

\_.

	Participants				Non-responders	ers	Non-participants	ants
					0			
Chara cteristics	N = 183	Female	Male	þ value	N = 58	þ value	N=51	þ value
Exercise habits (s 30 min per day)								
0 days per week	94 (51.4)	22 (50.0)	72 (51.8)	0.783	26 (44.8)	<0.0001	22 (43.1)	0.001
I-2 days per week	22 (12.0)	5 (11.4)	17 (12.2)		22 (38.0)		19 (37.3)	
3-4 days per week	25 (13.7)	8 (18.2)	17 (12.2)		5 (8.6)		4 (7.8)	
>4 days per week	42 (23.0)	9 (20.5)	33 (23.7)		5 (8.6)		6 (11.8)	
Alcohol consumption (>7/14 units per week)	24 (13.1)	I (2.3)	23 (16.6)	0.011	5 (8.6)	0.488	9 (17.7)	0.494
Obesity (BMI, kg/m <sup>2</sup> )								
Obese (s 30)	44 (24.0)	10 (22.7)	35 (25.2)	<0.0001	4 (7.1)	0.004	18 (35.3)	0.110
Overweight (25–30)	94 (51.4)	14 (31.8)	80 (57.6)		28 (50.0)		18 (35.3)	
Normal (<25)	45 (24.6)	20 (45.5)	24 (17.3)		24 (42.9)		15 (29.4)	
Comorbidity								
Lung disease	16 (8.7)	5 (11.4)	11 (7.9)	0.541	12 (20.7)	0.019	10 (19.6)	0.042
Ischaemic stroke	11 (6.0)	3 (6.8)	8 (5.8)	0.727	5 (8.6)	0.545	7 (13.7)	0.078
Peripheral vascular disease	12 (6.6)	I (2.3)	11 (7.9)	0.299	6 (10.3)	0.390	4 (7.8)	0.756
Renal failure	I (0.6)	0 (0.0)	1 (0.7)	000.1	0 (0.0)	000 <sup>.</sup> I	4 (7.8)	0.009
Medical treated mental depression	10 (5.5)	3 (6.8)	7 (5.0)	0.705	7 (12.1)	0.136	6 (11.8)	0.124
Musculoskeletal disease	17 (9.3)	5 (11.4)	12 (8.6)	0.561	13 (22.4)	0.012	3 (5.9)	0.578
Self-care management stratification								
High	139 (76.0)	38 (86.4)	101 (72.7)	0.071		<0.0001		<0.0001
Low	44 (24.0)	6 (13.6)	38 (27.3)		30 (51.7)		29 (56.9)	
NSTEMI: non-ST segment myocardial infarction; STEMI: ST segment myocardial infarction; PCI: percutaneous transluminal coronary intervention; CABG: coronary artery bypass graft; IHD: ischaemic heart disease; stratification; according to the Chronic Care Model; BMI: body mass index. Values are numbers (%) unless stated mean (SD).	: ST segment myocarc Model; BMI: body ma	dial infarction; PCI: ss index.	percutaneous transl	uminal coronary	intervention; CABC	i: coronary artery	bypass graft; IHD: is	chaemic heart

Study variable	Adm to C	ission R		3 mc disch	onths at arge		12 m follo	nonths w-up		Differend	es
Cardiovascular risk factors										0–3 mo	3–12 mo
BMI (kg/m <sup>2</sup> ), mean (SD)	183	27.5	3.8	178	27.5	3.8	183	27.3	4.0	0.890	0.026
Blood pressure (mmHg), mean (SD)											
Systolic	183	135.5	19.5	182	136.9	18.6	182	138.7	19.8	0.345	0.299
Diastolic	183	79.8	11.4	182	81.2	9.8	182	83.9	9.7	0.073	0.0005
Blood test (non-fasting), mean (SD)											
Total-cholesterol (mmol/l)	183	4.2	1.0	183	3.9	0.8	183	3.9	0.7	<0.0001	0.316
LDL (mmol/l)	181	2.4	0.8	183	2.1	0.6	183	2.1	0.6	<0.0001	0.459
HDL (mmol/l)	181	1.3	0.5	183	1.3	0.4	183	1.4	0.4	0.130	0.027
Triglyceride (mmol/l)	181	1.5	0.9	183	1.5	0.9	182	1.5	1.0	0.110	0.735
HbA1c (%)*	32	0.070	0.011	31	0.069	0.013	32	0.070	0.014	0.400	0.463
Medication intake											
Aspirin	183	179	97.8	181	175	96.7	183	177.0	96.7	NS	
Clopidogrel/Prasugrel	183	134	73.2	181	132	72.9	181	89.0	48.6		
Statin	183	174	95.I	181	173	95.6	183	173.0	94.5		
Non-statin	183	6	3.3	181	6	3.3	183	7.0	3.8		
Beta-blocker	183	127	69.4	181	120	66.3	183	117.0	63.9		
ACE-inhibitor	183	63	34.4	181	65	35.9	183	80.0	43.7		
Lifestyle behaviours											
Alcohol consumption (>7/14 units per week)	183	20	11.0	181	24	13.3	183	25.0	13.8	0.102	0.564
Current smokers											
Number	183	22	12.1	181	19	10.5	181	18.0	9.9	0.083	0.655
Cigarettes a day, mean (SD)		10	7.2	21	8	5.5	21	8.5	6.2	0.170	I
Combined treadmill exercise/Borg15 talk											
Test, mean (SD)											
METS at Borg15	176	7.5	1.9	100	8.3	1.3	172	8.3	2.6	0.007	0.788
Alternative 6MWT (meter)	7										
Psycosocial											
Self-care management											
High	183	139	76.0	183	161	88.0	183	168.0	91.8	0.0002	0.071
Low	183	44	24.0	183	22	12.0	183	15.0	8.2		
Health status, mean (SD)											
SF12 physical component score (pcs)	137	44	9.9	137	48.8	9.1				<0.0001	
SFI2 mental component score (mcs)	137	50	10.8	137	52.3	8.9				0.005	
SF12 physical component score (pcs)				4	48.7	9.2	141	47	10.4		0.002
SF12 mental component score (mcs)				141	53.0	8.4	141	53	9.7		0.899
Anxiety											
HADS-A <8	161	125	77.6	161	134	83.2	161	137	85.I	0.083	0.5637
HADS-A >8	161	36	22.4	161	27	16.8	161	24	14.9		
Depression											
HADS-D <8	161	138	85.7	161	148	91.9	161	149	92.5	0.0075	0.7055
HADS-D >8	161	23	14.3	161	13	8.I	161	12	7.4		

**Table 3.** Outcome after cardiac rehabilitation for cohort at admission compared to three months at discharge and at one-year follow-up.<sup>a</sup>

mo: months; NS: non significant; BMI: body mass index; METS: 3,5 ml O<sub>2</sub>/kg/min; 6MWT: 6-min walk test; \*HbA1c: only measured for diabetic. <sup>a</sup>Self-care management was determined after stratification according to the Chronic Care Model. Health status (SF-12v2) and Hospital Anxiety and Depression Scale (HADS); estimated data were calculated for participants who responded at both control times. Physical component score (pcs) and mental component score (mcs). Continuous clinical variable, self-care management, Short-Form 12 version 2 (SF-12v2) and Hospital Anxiety and Depression score (HADS). Values are numbers (%) unless stated.

# Ethics

According to Danish law, this study did not need approval by the Regional Ethics Committee. This was confirmed by the Chair of the South Danish Regional Ethics Committee. The Danish Data Protection Agency approved the research database (J no. 2008-58-0034). Signed informed consent was obtained from all participants.

# Statistical analysis

Characteristics and outcomes were reported as means (SD) for normally distributed continuous variables, median (interquartile range (IOR)) for skewed continuous variables and number (%) for categorical variables. The effectiveness of the programme was estimated in terms of the differences between admission (phase IIa) and three months at discharge from hospital (phase IIb), and between discharge and 12 months follow-up from admission (phase III). We reported 95% confidence intervals to indicate the precision of the estimates. Wilcoxon signed-rank test was used to compare differences. A p value of 0.05 or less was used to signify statistical significance. The estimated data were calculated for the participants who responded at the comparative follow-up times (Table 3). Predefined subgroup analysis on sex was performed. Data were analysed using Stata software, version 12 (StataCorp, College Station, TX).

# Results

# Participant flow

Of the 292 patients invited to the study, 51 (17.5%) refused to participate (Figure 2). The non-participants were older, had known IHD and other chronic diseases, see Table 2. Fifty-eight of the included patients did not contribute to the analyses because of drop out or non-response to the questionnaires.

Six men died. Three of the non-participants (2 of myocardial re-infarction, 1 of cancer disease) and three of the non-responders in the cohort died (1 of myocardial re-infarction, 2 died suddenly without clarifying autopsy out of hospital). Of 241 patients, 183 (75.9%) provided data for analysis (Figure 2).

# Participant baseline characteristics

Characteristics are shown in Table 2. The mean age was 63.8 (SD 9.0). The majority were men (76%) significantly younger than the women (mean age  $62.9 \pm$  SD 8.6 compared to  $66.9 \pm 9.7$ ; p = 0.020). The majority of the participants were Danish (97.8%), were married/cohabiting (83.2%), retired 57.8%) and lived in

immovable properties (77%). Statistical significant differences were found between female and male. More females lived alone (n = 30, female 32.6% versus male 11.9%, p = 0.004), were retired (n = 104, female 72.2% versus male 52.9%, p = 0.040) and had a shorter education, <3 years after primary school (n = 116, female 86.4% versus male 56.1%, p < 0.0001), respectively.

Most of the participants (66.1%) attended the CR after PCI without acute MI (Table 2). Of all, 17.5% had CABG (21.6% men compared to women 4.6%; p = 0.011). Of all, 20.8% had known IHD. Concerning risk factors, 50.3% had known family history of IHD, 70.5% had a smoking history. Few had diabetes (17.5%). Of all, 70.5% had medically treated hypertension and 91.3% had medically treated hyperlipidaemia at admission. Of all, 50.4% of the participants had low physical activity level (0 days/week with  $\geq$  30 min/day).

Of all, 16.6% of men had alcohol consumption above the limits recommended by the Danish Health and Medicines Authority (men <14 and women <7 units/week) compared to 2.3% of females (p = 0.011). Men were more obese (p < 0.0001). Of all, 26% of the participants had low self-care management at admission with no sex difference.

#### Non-participants and non-responders characteristics

Overall the CR non-participants and the non-responders in the study had more disease complexity and lower level of self-care management compared to the participants (Table 2). The non-participants differed significantly on baseline characteristics in age, type of MI and previous known IHD compared to the participants. They were older (mean age 68 (SD 11.6) compared to 63.8 (9.0); p = 0.006), fewer have had ST segment myocardial infarction (STEMI) at present (p=0.003) and more had known IHD (p=0.026). Furthermore, they had significantly more risk factors to CVD, e.g. more with a smoking history (p = 0.001), statin treated (p=0.03), lower physical activity (p=0.001) and comorbidity with lung disease (p=0.042) and renal failure (p=0.009). Moreover, they were stratified with lower level of self-care management (p < 0.0001).

The non-responders were compared to the participants followed significantly in risk factors for CVD, e.g. more with a smoking history (p < 0.0001), insulin treated diabetic (p = 0.022), statin treated (p < 0.0001), lower physical activity (p < 0.0001), lesser obesity (p = 0.004), comorbidity with lung disease (p = 0.019) and musculoskeletal disease (p = 0.012). Moreover, they had lower levels of self-care management (p < 0.0001). The same pattern was seen comparing the non-participants to the participants (Table 2).

No difference in comorbidity was found between groups concerning previously ischaemic stroke, medically treated mental depression or peripheral vascular disease. The groups were comparable on other clinical variables. No sex differences were found.

# The clinical and risk behavioural outcomes after three months and one year

Table 3 shows the difference in outcomes. No difference at discharge (3 months) was found in BMI, whereas significant improvement in BMI was found at one-year follow-up (mean -0.26, 95% CI: -0.50 to 0.03, p = 0.026).

No differences were found in systolic blood pressure (SBP). The level of diastolic blood pressure (DBP) was higher at one-year follow-up compared to three months at discharge (mean 2.69, 95% CI: 1.20–4.17, p=0.0005). Total-cholesterol (difference mean -0.37, 95% CI: -0.51 to 0.22, p < 0.0001) and LDL (difference mean -0.31, 95% CI: -0.19 to 0.42, p < 0.0001) were significantly decreased due to treatment (for statins and aspirin, respectively, 94.5% and 96.7% at the one-year follow-up with no significant difference between the follow-up times). Total-cholesterol and LDL levels were maintained at one-year follow-up, whereas HDL increased (mean 0.05, 95% CI: 0.01-0.10, p = 0.027).

At admission 12.1% were smokers. Of all, 10.5% were still smokers at discharge and 9.9% at one-year follow-up. The differences were not significant. No differences on alcohol consumption were found.

At discharge from CR (3 months) significant improvement was found in metabolic equivalent of tasks (METS) compared to admission at the combined treadmill exercise/Borg15 talk test (mean 0.68, 95% CI: 0.19-1.17, p=0.007). After one-year the effect was maintained, but not further improved.

# The psychosocial outcomes after three month and one-year follow-up

Self-care management improved significantly at three months, as 12.0% had low level compared to 24% initial. A further decrease was seen at one-year follow-up (8.2%).

Health Status (SF12) improved significantly at three months compared to admission (pcs mean 4.63, 95% CI: 3.02–6.24, p = 0.000 and mcs mean 2.41, 95% CI: 0.75–4.08, p = 0.005). At the one-year follow-up further improvement in the pcs was found (mean 2.2, 95% CI: 0.80–3.60, p = 0.002) whereas the effect on mcs was maintained.

Of all, 14.3% had depression symptoms at admission to CR (HADS depression (HADS-D)  $\geq 8$ ).

At three months 8.1% had depression symptoms significantly reduced (p = 0.008). At the one-year follow-up the reduction was maintained (7.4%). No significant difference was found in HADS anxiety ( $\geq 8$ ) (Table 3).

No differences were found in sex at any of follow-up times.

# Discussion

This one-year follow-up study supports the evidence of the principles of the Chronic Care Model and documents the effectiveness of CR across local and regional health authorities led by a NCM providing risk stratified care management.<sup>9,10</sup> Thus, the study showed improvement in most clinical and risk behavioural factors, self-care management and self-reported psychosocial factors (SF12 and HADS). Effects at discharge were on total-cholesterol, LDL, functional capacities, self-care management, self-reported health Health status Short Form 12 version (SF12) and depression symptoms. At one-year follow-up the achieved benefits were maintained apart from a decrease in SF12 physical component and an increase in DBP. Improvements were moreover evident for BMI and HDL, consistent with the emphasis on behavioural lifestyle improvement. Optimal medical treatment was ascertained at discharge and at the one-year follow-up.

The results suggest that adherence to a specialised CR centre with dedicated long-term efforts beyond the early phase is not necessarily needed to maintain improvements in health outcomes. A locally anchored CR, where the NCM provides continuity, may be as effective as a pure hospital-based programme.<sup>8</sup> Furthermore, the programme may enhance women's compliance which is a challenge in CR.<sup>5,6</sup>

The outcomes at the one-year follow-up support the strengths of the GoHeart compared to other studies where compliance to lifestyle and treatment regimens have declined after six 6 months.<sup>17</sup> In contrast, the large multi-centre randomised controlled RAMIT-trial<sup>18</sup> investigating CR in England and Wales after two years, compared to usual care, showed no effect on mortality, cardiac or psychological morbidity, risk factors, health-related quality of life or activity. However, the RAMIT study was criticised for methodological weaknesses and a lack of components from modern CR programme.<sup>19</sup> The increase in DBP at the oneyear follow-up was unexpected, but in accordance to guidelines of ESC.<sup>20</sup> The achieved health behaviour at one-year -follow-up is not in accordance with general Danish guidelines, but not alarming. For example, 9.9% patients smoked compared to 19.0% in the study by Larsen et al.,<sup>21</sup> and 17% in the general Danish population.

In our study, 14.3% of the participants had depression symptoms at admission to CR (HADS-D >8), which was reduced to 8.1% at three months (Table 2) and maintained at the one-year follow-up (7.4%). The prevalence of depression in the Danish population is 3-4%. However, that may be underestimated, as it is based on patient registers and does not include depression diagnosed outside the hospital.<sup>22</sup> In a recent Danish study of 897 patients discharged with firsttime MI. depressive symptoms were found in 18.6% using the HADS-D Scale. Depressive symptoms following first-time MI were shown to be an independent prognostic risk factor for death, but not for new cardiovascular events.<sup>23</sup> The risk of depression after MI is well-documented and associated with increased mortality.<sup>24-27</sup> In GoHeart, the majority had PCI without acute MI (66.1%). The findings support that the diagnosis of CVD is associated with depression and indicates the need for routine screening and for addressing depression in modern CR.<sup>8,25,28</sup> Depression symptoms in the EUROSPIRE III survey were more prevalent in women than in men,<sup>29</sup> whereas no sex differences were found in our study.

We found no differences in HADS anxiety ( $\geq 8$ ) (Table 2). However, the tendency was in the right direction. The prevalence of people with anxiety symptoms decreased from 22.4% at admission to 16.8% at three months and to 14.9% at the one-year follow-up. The level of anxiety at the three-month follow-up was lower than in a Danish study in people with AMI, where 23.6% reported anxiety (HADS-A) three month after the event. The one-year follow-up results corresponded to the Danish population, and to a Norwegian population in the study by Hanssen et al.<sup>26</sup>

Health Status (SF12) in both physical and mental components was improved significantly at three months. At the one-year follow-up further improvement in the physical component was found.

#### Strengths and limitations

GoHeart is a follow-up study with participants undergoing a standardised CR programme according to offered session length, exercise training, time and duration at hospital and at the health centre. The different components are well described, which a strength for future implementation. The fact that health professionals (NCM, physicians, physiotherapist, etc.) participated in the planning phase, and actively contributed to ensure continuity and to help patients to navigate in the health system, may be a reason for the outcome.

All measurements were undertaken by trained staff following procedures, and information bias is likely to be low. Self-reported data from questionnaires may have potential limitations due to recall bias and social-desirable responses, but the impact may be diminished due to analysing differences.

The main limitation is the lack of a control group, e.g. a group given the previously hospital-based CR intervention before the transition to the municipal responsibility, or a group without a NCM. The characteristics of the non-participants and non-responders having more disease complexity and a lower level of self-care management compared to the participants (Table 2) reveals unresolved critical items in CR. The results are consistent with other studies showing that prevention needs to be individualised.<sup>30</sup>

Future CR studies should be evaluated in randomised controlled trials. Further, new studies should be designed to understand organisation barriers for Shared Care and health economic issues of CR across sectors.

The GoHeart programme calls for further health services research including the patient's perspectives on achieving rehabilitation in local settings, and how these interventions could be differentiated according to risk stratification, including self-care.

#### Acknowledgements

The authors acknowledge the assistance of nurse case manager Vibeke Pind Haslev, Department of Cardiology, Lillebaelt Hospital Vejle. The authors also wish to thank all patients who agreed to participate and the staff at the Municipal Health Centre Vejle for their valuable help.

#### **Declaration of Conflicting Interests**

None declared.

#### Funding

The work was supported by the Region of South Denmark through the Danish Health and Medicines Authority.

#### Ethical approval

None.

# Guarantor

VBH is the guarantor for all the content presented in this paper.

### Contributorship

VBH conceived the study question, and was responsible for the data collection. VBH and HTM were involved in the design phase, the analysis and the interpretation of the results. VBH and HTM drafted the manuscript together, and approved the final version.

#### References

1. Integration of health care delivery. Report of a WHO study group. *World Health Organ Tech Rep Ser* 1996; 861: 1–68.

- Cook RI, Render M and Woods DD. Gaps in the continuity of care and progress on patient safety. *BMJ* 2000; 320: 791–794.
- Wood DA, Kotseva K, Connolly S, et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. *Lancet* 2008; 371: 1999–2012.
- 4. Voogdt-Pruis HR, Vrijhoef HJ, Beusmans GH, et al. Quality improvement of nurse-led aftercare to outpatients with coronary heart disease: report of a case study. *Int J Qual Health Care* 2012; 24: 286–292.
- Flink LE, Sciacca RR, Bier ML, et al. Women at risk for cardiovascular disease lack knowledge of heart attack symptoms. *Clin Cardiol* 2013; 36: 133–138.
- Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. *J Am Coll Cardiol* 2007; 49: 1230–1250.
- Hansen VB, Haslev VP, Kring A, et al. Tværsektoriel forløbskoordinator kan mindske frafald fra hjerterehbilitering (In Danish). Danish Med Bull 2014; 5: 440–443.
- Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). *Int J Behav Med* 2012; 19(4): 403–488.
- Ouwens M, Wollersheim H, Hermens R, et al. Integrated care programmes for chronically ill patients: a review of systematic reviews. *Int J Qual Health Care* 2005; 17: 141–146.
- Bodenheimer T, Wagner EH and Grumbach K. Improving primary care for patients with chronic illness. *JAMA* 2002; 288: 1775–1779.
- 11. Bodenheimer T, Wagner EH and Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, part 2. *JAMA* 2002; 288: 1909–1914.
- Fletcher GF, Balady GJ, Amsterdam EA, et al. Exercise standards for testing and training: a statement for healthcare professionals from the American heart association. *Circulation* 2001; 104: 1694–1740.
- Brawner CA, Vanzant MA, Ehrman JK, et al. Guiding exercise using the talk test among patients with coronary artery disease. *J Cardiopulm Rehabil* 2006; 26: 72–75; quiz 76–77.
- Ware J Jr, Kosinski M and Keller SD. A 12-item shortform health survey: construction of scales and preliminary tests of reliability and validity. *Med Care* 1996; 34: 220–233.
- Zigmond AS and Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand* 1983; 67: 361–370.
- Roberts SB, Bonnici DM, Mackinnon AJ, et al. Psychometric evaluation of the hospital anxiety and depression scale (HADS) among female cardiac patients. *Br J Health Psychol* 2001; 6: 373–383.
- 17. Chow CK, Jolly S, Rao-Melacini P, Fox KA, et al. Association of diet, exercise, and smoking modification

with risk of early cardiovascular events after acute coronary syndromes. *Circulation* 2010; 121: 750–758.

- West RR, Jones DA and Henderson AH. Rehabilitation after myocardial infarction trial (RAMIT): multi-centre randomised controlled trial of comprehensive cardiac rehabilitation in patients following acute myocardial infarction. *Heart* 2012; 98: 637–644.
- BACPR Elected Council Members. RAMIT presents an outdated version of cardiac rehabilitation. *Heart* 2012; 98: 672; author reply 673–674.
- Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ ESC practice guidelines for the management of arterial hypertension. *Blood Press* 2013; 22(4): 193–278.
- Larsen KK, Vestergaard M, Sondergaard J, et al. Rehabilitation status three months after first-time myocardial infarction. *Scand J Prim Health Care* 2011; 29: 210–215.
- Olsen LR, Munk-Jorgensen P and Bech P. The prevalence of depression in Denmark. *Danish Med Bull* 2007; 169: 1425–1426.
- Larsen KK, Vestergaard M, Sondergaard J, et al. Screening for depression in patients with myocardial infarction by general practitioners. *Eur J Prev Cardiol* 2013; 20: 800–806.
- 24. Chauvet-Gelinier JC, Trojak B, Verges-Patois B, et al. Review on depression and coronary heart disease. *Arch Cardiovasc Dis* 2013; 106: 103–110.
- 25. Gasse C, Laursen TM and Baune BT. Major depression and first-time hospitalization with ischemic heart disease, cardiac procedures and mortality in the general population: a retrospective Danish population-based cohort study. *Eur J Prev Cardiol*. Epub ahead of print 2012.
- 26. Hanssen TA, Nordrehaug JE, Eide GE, et al. Anxiety and depression after acute myocardial infarction: an 18-month follow-up study with repeated measures and comparison with a reference population. *Eur J Cardiovasc Prev Rehabil* 2009; 16: 651–659.
- Larsen KK, Agerbo E, Christensen B, Sondergaard J, et al. Myocardial infarction and risk of suicide: a population-based case-control study. *Circulation* 2010; 122: 2388–2393.
- 28. Lichtman JH, Bigger JT, Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American heart association prevention committee of the council on cardiovascular nursing, council on clinical cardiology, council on epidemiology and prevention, and interdisciplinary council on quality of care and outcomes research: Endorsed by the American psychiatric association. *Circulation* 2008; 118: 1768–1775.
- Pajak A, Jankowski P, Kotseva K, et al. Depression, anxiety, and risk factor control in patients after hospitalization for coronary heart disease: The EUROASPIRE III study. *Eur J Prev Cardiol* 2013; 20: 331–340.
- Clark AM, King-Shier KM, Duncan A, et al. Factors influencing referral to cardiac rehabilitation and secondary prevention programs: a systematic review. *Eur J Prev Cardiol* 2013; 20: 692–700.